EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly With advanCed breasT Cancer
- Registration Number
- NCT02783222
- Lead Sponsor
- Fondazione Sandro Pitigliani
- Brief Summary
This is a randomized study evaluating the efficacy and impact on function of two different doses of nab-Paclitaxel in elderly patients with advanced breast cancer.
- Detailed Description
This open-label, randomized phase II trial evaluates in parallel two doses of nab-Paclitaxel (100 and 125mg/m2) given weekly for 3 weeks every 28 days, in elderly women aged 65 years or older, as first line treatment for advanced breast cancer (locally recurrent or metastatic). A short geriatric evaluation of co-morbidity and functional status will be performed before study entry. The functional status will be monitored at baseline and at every cycles during treatment.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 160
- Histologically or cytologically confirmed breast cancer, locally recurrent and/or metastatic; any estrogen/progesterone receptor status; HER2 receptor negative OR HER2 positive but with contraindication to anti-HER2 therapy (e.g. known congestive cardiac failure).
- Measurable disease or non-measurable but evaluable disease according to RECIST 1.1 criteria
- ECOG performance status 0-2
- Estimated life expectancy of ≥ 12 weeks
- No known active/symptomatic CNS metastases
- No previous chemotherapy for breast cancer in the advanced setting
- Adequate organ function including ( Hemoglobin ≥ 9g/dL; Absolute neutrophil count ≥ 1.5 x 10^9/L; Platelets ≥ 100 x 10^9/L; Bilirubin ≤ 1.5 mg/dL; ALT and AST ≤ 3 x ULN (with or without known hepatic metastases); ALP ≤ 2.5 x ULN; Serum creatinine ≤ 1.5 ULN or calculated creatinine clearance (CrCl) ≥ 50mL/min according to the Cockcroft Gault formula
- Written informed consent (according to ICH/GCP and national/local regulations)
- Significant peripheral neuropathy (significant peripheral neuropathy is defined as ≥ grade 2 on CTCAE v4.0 criteria)
- Clinically significant comorbidities including: uncontrolled cardiac arrhythmias (except rate-controlled atrial fibrillation), NYHA class III or IV cardiac failure, uncontrolled diabetes, hypertension or other medical conditions that may interfere with assessment of toxicity
- Other malignancy within the last 5 years, except for adequately treated non-melanomatous skin cancers, cervical intraepithelial neoplasia or cervical carcinoma in situ
- Intake of any concomitant medications or therapies that may potentially interact with the trial agent. Any prohibited medication must be discontinued at least 14 days prior to trial entry
- Presence of any psychological, familial, sociological or geographical condition that may potentially hamper compliance with the study protocol and follow-up schedule; these conditions should be discussed with the patient before trial registration
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm B Nab-paclitaxel Nab-paclitaxel 125 mg/mq weekly for 3 out of every 4 weeks Arm A Nab-paclitaxel Nab-paclitaxel 100 mg/mq weekly for 3 out of every 4 weeks
- Primary Outcome Measures
Name Time Method Event-free survival (EFS) Every 12 weeks, until disease progression or death or trial completion (12 months after randomization of the last patient). Event is defined as either disease progression or death, or functional decline. Functional decline is defined as decreased in at least 1 point from baseline ADL, and/or IADL, as confirmed by the investigator as treatment-related and confirmed at the subsequent cycle
- Secondary Outcome Measures
Name Time Method Objective response rate (ORR) Every 12 weeks, until disease progression or trial completion (12 months after randomization of the last patient). Documentation of disease response or progression will be based on RECIST 1.1 criteria
Clinical benefit rate (CBR) Every 12 weeks, until disease progression or trial completion (12 months after randomization of the last patient) Documentation of disease response or progression will be based on RECIST 1.1 criteria
Progression free survival (PFS) Every 12 weeks, until disease progression or death or trial completion (12 months after randomization of the last patient) Documentation of disease progression will be based on RECIST 1.1 criteria
Overall survival (OS) Every 12 weeks until death or trial completion (12 months after randomization of the last patient) Documentation of death
Incidence of adverse events Every 12 weeks until event occurrence or trial completion (12 months after randomization of the last patient) Severity will be reported based on CTCAE v4.0
Trial Locations
- Locations (14)
Spedali Civili Brescia
🇮🇹Brescia, Italy
Fondazione Maugeri
🇮🇹Pavia, Italy
Centro Di Riferimento Oncologico
🇮🇹Aviano, Italy
Azienda Ospedaliera Papa Giovanni Xxiii
🇮🇹Bergamo, Italy
Ausl 12 Viareggio
🇮🇹Lucca, Italy
Istituto Europeo Oncologia
🇮🇹Milano, Italy
A.O.U. S. Maria Della Misericordia Di Udine
🇮🇹Udine, Italy
Ospedale Civile Maggiore
🇮🇹Verona, Italy
A.O.U. Ospedali Riuniti
🇮🇹Ancona, Italy
Ospedale Vito Fazzi
🇮🇹Lecce, Italy
A.O.U. Federico Ii Di Napoli
🇮🇹Napoli, Italy
Istituto Oncologico Veneto
🇮🇹Padova, Italy
Ospedale Antonio Perrino
🇮🇹Brindisi, Italy
Ospedale Ss. Trinita'
🇮🇹Frosinone, Italy